NCT04659447

Brief Summary

Anterior cruciate ligament (ACL) injury is a common knee injury, which seriously affects the living ability and sport level of the injured. ACL reconstruction is the main method to treat ACL injury. Due to the reconstructive ligament needs a tendon bone healing and ligament maturation, therefore, in the ACL anatomical study, reconstruction surgery and reconstruction materials under the condition of constant progress, how to improve the ACL reconstruction of tendon bone healing and shorten the time of the ligament mature, improve the clinical effect of ACL reconstruction, has become the focus in the ACL reconstruction. Autologous platelet-rich plasma (PRP) is full of growth factors and bioactive factors, which has the function of promoting tissue healing, anti-inflammatory and analgesic effects. At the same time of anterior cruciate ligament reconstruction, using autologous PRP in the bone channel might promote tendon bone healing and ligament maturing after ACL reconstruction, promote the recovery of proprioception, prevent bone channel expanding, shorten the postoperative recovery time, speed up the patients recovery exercise ability, improve the clinical effect of ACL reconstruction. In this study, patients with ACL injuries were randomly divided into two groups: one group underwent ACL anatomical reconstruction, and the other group underwent ACL anatomical reconstruction with PRP. Various clinical scores, KT-2000, Biodex and imaging tests were used to evaluate the differences in the clinical effects of the two surgical methods in terms of postoperative pain, joint swelling, knee function, joint stability, muscle strength recovery, bone channel expanding, ligament vasinization, and ligament maturation.

Trial Health

35
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
60

participants targeted

Target at P75+ for phase_1

Timeline
Completed

Started Jul 2016

Longer than P75 for phase_1

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

July 1, 2016

Completed
4.4 years until next milestone

First Submitted

Initial submission to the registry

November 23, 2020

Completed
16 days until next milestone

First Posted

Study publicly available on registry

December 9, 2020

Completed
11 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 9, 2021

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

November 9, 2021

Completed
Last Updated

December 9, 2020

Status Verified

December 1, 2020

Enrollment Period

5.4 years

First QC Date

November 23, 2020

Last Update Submit

December 2, 2020

Conditions

Keywords

Anterior Cruciate Ligament Tearplatelet-rich plasma

Outcome Measures

Primary Outcomes (8)

  • tendon bone healing and ligament maturing

    The diameter of bone canal was evaluated by CT, it is measured in millimeters (mm). The tendon bone healing and ligament maturing was evaluated by MRI. According to the same level of anterior cruciate ligament, femoral canal, posterior cruciate ligament, background noise, with the diameter of 3.3 mm as the center, the lowest signal value point was measured, and the final point was compared to obtain the Signal-Noise Ratio.

    CT and MRI were performed on the fourth day after operation

  • tendon bone healing and ligament maturing

    The diameter of bone canal was evaluated by CT, it is measured in millimeters (mm). The tendon bone healing and ligament maturing was evaluated by MRI. According to the same level of anterior cruciate ligament, femoral canal, posterior cruciate ligament, background noise, with the diameter of 3.3 mm as the center, the lowest signal value point was measured, and the final point was compared to obtain the Signal-Noise Ratio.

    CT and MRI were performed on one year after operation

  • proprioception and Knee joint function

    KT-2000, it was used to assess the stability of the tibia and the results were expressed in millimeters. Biodex, it is used to assess the strength and function of joints. The contralateral knee joint was taken as the reference. The percentage of strength between the affected knee joint and the contralateral knee joint was obtained

    3 months after the operation

  • proprioception and Knee joint function

    KT-2000, it was used to assess the stability of the tibia and the results were expressed in millimeters. Biodex, it is used to assess the strength and function of joints. The contralateral knee joint was taken as the reference. The percentage of strength between the affected knee joint and the contralateral knee joint was obtained

    6 months after the operation

  • proprioception and Knee joint function

    KT-2000, it was used to assess the stability of the tibia and the results were expressed in millimeters. Biodex, it is used to assess the strength and function of joints. The contralateral knee joint was taken as the reference. The percentage of strength between the affected knee joint and the contralateral knee joint was obtained

    1 year after the operation

  • Knee pain

    Visual Analog Score for pain, it is used to assess the patient's pain, the full score is 10.

    3 months after the operation

  • Knee pain

    Visual Analog Score for pain, it is used to assess the patient's pain, the full score is 10.

    6 months after the operation

  • Knee pain

    Visual Analog Score for pain, it is used to assess the patient's pain, the full score is 10.

    1 year after the operation

Study Arms (2)

Platelet-Rich Plasma

EXPERIMENTAL

Four semitendinosus tendons and gracilis tendons are prepared. 4 ml platelet-rich plasma is completely absorbed by a gelatin sponge and fixed in the center of the four tendons. 4-0 absorbable line is used for fixation.Then we use conventional surgical techniques to reconstruct the ACL.

Drug: Platelet-Rich Plasma

control group

NO INTERVENTION

We performed conventional surgical techniques to reconstruction without using platelet-rich plasma.

Interventions

36 ml of peripheral blood is extracted from patients, and 4 ml of 3.8% sodium citrate is added for anticoagulation. After centrifugation for 2 times, 4 ml platelet-rich plasma will be prepared.Four semitendinosus tendons and gracilis tendons are prepared.

Platelet-Rich Plasma

Eligibility Criteria

Age15 Years - 50 Years
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64)

You may qualify if:

  • History of knee injury
  • History of knee instability
  • Anterior drawer test (+), or / and Lachman test (+)
  • The tear of anterior cruciate ligament was confirmed by MRI

You may not qualify if:

  • The injury of other ligaments of knee joint, such as complex posterior cruciate ligament injury, lateral collateral ligament injury and medial collateral ligament injury above III degree
  • Patients with meniscus removed
  • Patients with moderate to severe articular cartilage injury
  • Patients with complex nerves and blood vessels injury
  • Patients with compound intra - and periarticular fractures of the knee
  • Patients with intra or periarticular fractures of the knee
  • Patients with contralateral knee instability
  • Patients with severe cardiovascular and cerebrovascular diseases

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Related Publications (1)

  • Gong H, Huang B, Zheng Z, Fu L, Chen L. Clinical Use of Platelet-Rich Plasma to Promote Tendon-Bone Healing and Graft Maturation in Anterior Cruciate Ligament Reconstruction-A Randomized Controlled Study. Indian J Orthop. 2022 Jan 27;56(5):805-811. doi: 10.1007/s43465-021-00533-z. eCollection 2022 May.

MeSH Terms

Conditions

Athletic InjuriesAnterior Cruciate Ligament Injuries

Condition Hierarchy (Ancestors)

Wounds and InjuriesKnee InjuriesLeg Injuries

Study Design

Study Type
interventional
Phase
phase 1
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, INVESTIGATOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

November 23, 2020

First Posted

December 9, 2020

Study Start

July 1, 2016

Primary Completion

November 9, 2021

Study Completion

November 9, 2021

Last Updated

December 9, 2020

Record last verified: 2020-12